B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.

  title={B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.},
  author={Ricarda Herr and Martin K{\"o}hler and Hana Andrlov{\'a} and Florian Weinberg and Yvonne M{\"o}ller and Sebastian Halbach and Lisa Lutz and Justin Mastroianni and Martin Klose and Nicola Bittermann and Silke Kowar and Robert Zeiser and Monilola A. Olayioye and Silke Lassmann and Hauke Busch and Melanie Boerries and Tilman Brummer},
  journal={Cancer research},
  volume={75 1},
BRAF mutations are associated with aggressive, less-differentiated and therapy-resistant colorectal carcinoma. However, the underlying mechanisms for these correlations remain unknown. To understand how oncogenic B-Raf contributes to carcinogenesis, in particular to aspects other than cellular proliferation and survival, we generated three isogenic human colorectal carcinoma cell line models in which we can dynamically modulate the expression of the B-Raf(V600E) oncoprotein. Doxycyclin… 

Figures from this paper

The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior

BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines

It is shown that BRAF inhibition leads to the upregulation of a variety of receptor tyrosine kinases (RTKs) in CRC cell lines, including not only the EGFR, but also human epidermal growth factor receptor (HER) 2 and HER3, which indicates that a broad suppression of RTK signaling might be beneficial and should be taken into account in future research addressing targeted therapy in BRAF-mutant CRC.

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment

It is shown that melanoma cells resistant to the BRAF inhibitor are characterized by a lower proliferation rate and they acquire a spindle-like shape, and combination therapy reduced their viability, as measured with a colorimetric cytotoxicity test, and decreased invasiveness.

Role of Furin in Colon Cancer Stem Cells Malignant Phenotype and Expression of LGR5 and NANOG in KRAS and BRAF-Mutated Colon Tumors

The findings indicate that PCs play an important role in the malignant phenotype of colon CSCs and stem cell markers’ expression and highlight PCs repression, particularly of Furin, to target colon tumors with KRAS or BRAF mutation.

BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation

A systematic comparison of the response of small and large intestinal organoids to oncogenic alterations suggests colonic organoid models to be better suited to model the human situation.

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance

Genetic alterations currently described in the literature and databases are summarized, indicating overlapping but also specific co-occurrences with either mutated BRAF or KRAS.

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.

Fascin1 accelerates serrated pathway carcinogenesis by remodeling adherens junctions and restoring Wnt signaling. Short title: Fascin1 accelerates serrated pathway colon cancers

In BRAFV600E-driven SCRCs, fascin1 remodels adherens junction mechanotransduction to activate oncogenic Wnt signaling which accelerates and amplifies tumor growth and metastasis, and plays a key role in generating a cooperating signaling pathway that facilitates the initiation and progression.



Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

The findings suggest that the administration of vemurafenib in combination with standard-of-care or novel targeted therapies may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mutation.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

An RNA-interference-based genetic screen in human cells is performed to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition, and it is reported that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAFs inhibition.

Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer.

It is proposed that transient up-regulation of fascin1 in colorectal cancer promotes the acquisition of migratory and invasive phenotypes that lead to metastasis, and the expression of Fascin1 is down-regulated when tumor cells reach their metastatic destination where migration ceases and proliferation is enhanced.

Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.

Results suggest the usefulness of JTP-74057 in therapeutic applications for colorectal cancer patients and its antitumor activities in vitro and in vivo, and sensitivity was enhanced by an Akt inhibitor.

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

The studies from Bettegowda and Misale and their colleagues show the effectiveness of analyzing circulating DNA from a variety of tumors and highlight the potential applications of this technology for early detection, monitoring resistance, and devising treatment plans to overcome resistance.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

It is found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustainedMAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.

Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation

Deletion of the mouse gene encoding Mig6 is shown to cause hyperactivation of endogenous epidermal growth factor receptor (EGFR) and sustained signaling through the mitogen-activated protein kinase (MAPK) pathway, resulting in overproliferation and impaired differentiation of Epidermal keratinocytes, indicating a tumor-suppressive role for Mig6.